exRNAdisease

General Information

Database ID:

exR0088180

RNA Name:

hsa-miR-33a-5p

RNA Type:

miRNA

Chromosome:

chr22

Starnd:

Coordinate:

Start Site(bp):

41900949

End Site(bp):

41900969

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
RBM33	chr7	155644451	155781485	+
ARCN1	chr11	118572390	118603033	+
CROT	chr7	87345681	87399795	+
PIM1	chr6	37170152	37175428	+
BRIP1	chr17	61679139	61863528	-
RAB11FIP2	chr10	118004916	118046941	-
ECHDC1	chr6	127288712	127343609	-
NFAT5	chr16	69565094	69704666	+
ZBTB34	chr9	126860665	126885878	+
EIF5A2	chr3	170888418	170908644	-
XRN1	chr3	142306607	142448062	-
WDFY3	chr4	84669610	84966391	-
CERK	chr22	46684410	46738252	-
IGF1R	chr15	98648539	98964530	+
MYO19	chr17	36495633	36543435	-
E2F3	chr6	20401879	20493714	+
AFF4	chr5	132875395	132963634	-
DDX5	chr17	64498254	64508199	-
RCAN1	chr21	34513142	34615113	-
GLCCI1	chr7	7968796	8094272	+
ROBO1	chr3	78597239	79767998	-
RNF11	chr1	51236273	51273447	+
AFF3	chr2	99545419	100192428	-
ZDHHC9	chrX	129803288	129843909	-
ADCY9	chr16	3953387	4116442	-
ZFYVE16	chr5	80408013	80483379	+
ZNF148	chr3	125225561	125375354	-
MAPK1IP1L	chr14	55051647	55070194	+
CREM	chr10	35126791	35212958	+
KPNA4	chr3	160495007	160565571	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000540	chr14	55799534	55821940	+
hsa_circ_0001349	chr3	152132729	152150709	+
hsa_circ_0000642	chr15	80390757	80415142	+
hsa_circ_0000643	chr15	80412669	80415142	+
hsa_circ_0000284	chr11	33307958	33309057	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC023509.1	chr12	53441741	53467528	+
DANCR	chr4	52712404	52720351	+
FGD5-AS1	chr3	14920347	14948424	-
MCF2L-AS1	chr13	112967484	112968824	-
NEAT1	chr11	65422774	65445540	+

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.